Q2 FY2026 EarningsQ2 FY2026 results significantly beat expectations, with a GAAP EPS loss of -$0.13 vs. -$0.17 consensus. Collaboration revenue of $4.6M strongly outperformed the $2.2K consensus, while total operating expenses of $51.6M were lower than anticipated. Management provided a positive liquidity update, extending the cash runway into 2029 with $423.6M in cash, supported by RMAT and Fast Track designations for Cema-Cel.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Allogene Therapeutics(ALLO) the Revenue is 4.64 K (--%), Beat estimate;the EBIT is -46.92 M (+17.42%), Beat estimate;the EPS is -0.13 (+43.48%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITExceed expectations
-0.05B17.42%
-0.05B9.62%
+0.00B7.80%
EPSExceed expectations
-0.1343.48%
-0.169926.14%
+0.039917.34%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf